跳至主要内容
临床试验/RPCEC00000411
RPCEC00000411尚未招募2 期

Evaluation of the effect and safety of Jusvinza in severe patients with Acquired Community Pneumonia - VINSENT

Center for Genetic Engineering and Biotechnology (CGIB), the Havana0 个研究点目标入组 60 人开始时间: 2022年10月14日最近更新:
适应症

试验速览

阶段
2 期
状态
尚未招募
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized controlled trial. Masking: Double Blind. Control group: Placebo. Assignment: Parallel. Purpose: Treatment

入排标准

年龄范围
18 years 至 one(—)
性别
All

入选标准

  • 1. Patients with Age = 18
  • 2. Willingness of the patient through the signing of the informed consent.
  • 3. Patients with diagnosis of SACP (Severe Acquired Community Pneumonia).

排除标准

  • 1. Patient with Septic Shock.
  • 2. Patient with Severe Acute Respiratory Distress Syndrome.
  • 3. Hospitalized patient with a diagnosis of CAPg of more than 48 hours of evolution.
  • 4. Patient with prior treatment with JAK inhibitor, tocilizumab or other anti-IL6R or IL-6 inhibitor, IL-1 (Anakinra), Nimotuzumab and Itolizumab.
  • 5. Patients with significant deterioration of their underlying chronic disease that compromise imminent survival: diseases such as unresectable tumors, hematological diseases, Alzheimer's disease or AIDS, terminal chronic respiratory diseases requiring permanent oxygenation, prolonged bed rest due to cerebrovascular diseases.
  • 6. Obese patients (Body Mass Index > 30 kg/m2).
  • 7. Patient with Chronic Kidney Disease undergoing hemodialysis.
  • 8. Hypersensitivity to the product or any of its components.
  • 9. Patients with steroid use at immunosuppressive doses greater than 20 mg daily of Prednisone or equivalent.
  • 10. Psychiatric patients.
  • 11. History of SACP 30 days prior to inclusion.
  • 12. Pregnancy or lactation.

研究者

发起方
Center for Genetic Engineering and Biotechnology (CGIB), the Havana

相似试验